Subjects -> MEDICAL SCIENCES (Total: 8196 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (177 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2241 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

RHEUMATOLOGY (76 journals)

Showing 1 - 76 of 76 Journals sorted alphabetically
ACR Open Rheumatology     Open Access   (Followers: 6)
Advances in Rheumatology     Open Access   (Followers: 3)
African Journal of Rheumatology     Full-text available via subscription  
Aktuelle Rheumatologie     Hybrid Journal   (Followers: 2)
Annals of Rheumatology and Autoimmunity     Open Access   (Followers: 3)
Annals of the Rheumatic Diseases     Hybrid Journal   (Followers: 34)
Archives of Osteoporosis     Hybrid Journal   (Followers: 1)
Arthritis & Rheumatology     Hybrid Journal   (Followers: 65)
Arthritis Care & Research     Hybrid Journal   (Followers: 37)
Arthritis Research & Therapy     Open Access   (Followers: 14)
Australasian Musculoskeletal Medicine     Full-text available via subscription   (Followers: 5)
Best Practice & Research Clinical Rheumatology     Hybrid Journal   (Followers: 17)
BMC Musculoskeletal Disorders     Open Access   (Followers: 29)
BMC Rheumatology     Open Access   (Followers: 5)
Case Reports in Rheumatology     Open Access   (Followers: 10)
Clinical and Experimental Rheumatology     Full-text available via subscription   (Followers: 3)
Clinical Medicine Insights : Arthritis and Musculoskeletal Disorders     Open Access   (Followers: 3)
Clinical Rheumatology     Hybrid Journal   (Followers: 22)
Current Opinion in Rheumatology     Hybrid Journal   (Followers: 13)
Current Reviews in Musculoskeletal Medicine     Open Access   (Followers: 13)
Current Rheumatology Reports     Hybrid Journal   (Followers: 3)
Current Rheumatology Reviews     Hybrid Journal   (Followers: 4)
Current Treatment Options in Rheumatology     Hybrid Journal  
Egyptian Rheumatologist     Open Access   (Followers: 1)
Egyptian Rheumatology and Rehabilitation     Open Access   (Followers: 2)
Forum Reumatologiczne     Hybrid Journal  
Future Rheumatology     Full-text available via subscription   (Followers: 1)
Gait & Posture     Hybrid Journal   (Followers: 17)
Indian Journal of Rheumatology     Open Access   (Followers: 1)
Indonesian Journal of Rheumatology     Open Access  
International Journal of Clinical Rheumatology     Open Access   (Followers: 5)
International Journal of Rheumatic Diseases     Hybrid Journal   (Followers: 2)
International Journal of Rheumatology     Open Access   (Followers: 6)
International Musculoskeletal Medicine     Hybrid Journal   (Followers: 7)
Internet Journal of Rheumatology and Clinical Immunology     Open Access   (Followers: 4)
JCR Journal of Clinical Rheumatology     Hybrid Journal   (Followers: 7)
Journal of Musculoskeletal Research     Hybrid Journal   (Followers: 9)
Journal of Orthopedics & Rheumatology     Open Access  
Journal of Rheumatology     Open Access   (Followers: 32)
Modern Rheumatology     Hybrid Journal   (Followers: 4)
Modern Rheumatology Case Reports     Hybrid Journal  
Multiple Sclerosis and Related Disorders     Hybrid Journal   (Followers: 8)
Musculoskeletal Care     Hybrid Journal   (Followers: 19)
MYOPAIN. A journal of myofascial pain and fibromyalgia     Hybrid Journal   (Followers: 16)
Nature Reviews Rheumatology     Full-text available via subscription   (Followers: 25)
OA Arthritis     Open Access   (Followers: 1)
OA Inflammation     Open Access  
Open Access Rheumatology: Research and Reviews     Open Access   (Followers: 3)
Open Journal of Orthopedics and Rheumatology     Open Access  
Open Journal of Rheumatology and Autoimmune Diseases     Open Access   (Followers: 4)
Open Rheumatology Journal     Open Access  
Orthopädie & Rheuma     Full-text available via subscription  
Osteoarthritis and Cartilage     Full-text available via subscription   (Followers: 20)
Osteoarthritis and Cartilage Open     Open Access  
Osteologie     Hybrid Journal  
Osteoporosis and Sarcopenia     Open Access  
Pain. Joints. Spine     Open Access   (Followers: 1)
Reumatismo     Open Access  
Reumatología Clínica (English Edition)     Full-text available via subscription  
Revista Argentina de Reumatología     Open Access  
Revista Colombiana de Reumatologia     Open Access  
Revista Colombiana de Reumatología (English Edition)     Hybrid Journal  
rheuma plus     Hybrid Journal  
Rheumatic Disease Clinics of North America     Full-text available via subscription   (Followers: 4)
Rheumatica Acta: Open Access     Open Access  
Rheumatology     Hybrid Journal   (Followers: 34)
Rheumatology & Autoimmunity     Open Access   (Followers: 9)
Rheumatology Advances in Practice     Open Access   (Followers: 1)
Rheumatology and Therapy     Open Access   (Followers: 3)
Rheumatology International     Hybrid Journal   (Followers: 3)
Rheumatology Practice and Research     Open Access  
RMD Open     Open Access   (Followers: 1)
Scandinavian Journal of Rheumatology     Hybrid Journal   (Followers: 5)
Seminars in Arthritis and Rheumatism     Hybrid Journal   (Followers: 8)
The Lancet Rheumatology     Hybrid Journal   (Followers: 1)
Zeitschrift fur Rheumatologie     Hybrid Journal   (Followers: 6)
Similar Journals
Journal Cover
Indian Journal of Rheumatology
Journal Prestige (SJR): 0.119
Number of Followers: 1  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0973-3698 - ISSN (Online) 0973-3701
Published by Medknow Publishers Homepage  [448 journals]
  • Coronavirus disease 2019 infection and autoimmunity: We see only a tip of
           the iceberg

    • Authors: R Naveen
      Pages: 107 - 109
      Abstract: R Naveen
      Indian Journal of Rheumatology 2022 17(2):107-109

      Citation: Indian Journal of Rheumatology 2022 17(2):107-109
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_113_22
      Issue No: Vol. 17, No. 2 (2022)
       
  • Individuals with reactive arthritis suffer from poor health-related
           quality of life akin to individuals with ankylosing spondylitis: A
           multigroup study

    • Authors: Prakash Gupta, Rajat Kharbanda, Maryam Abbasi, Roma Raj, Latika Gupta
      Pages: 110 - 117
      Abstract: Prakash Gupta, Rajat Kharbanda, Maryam Abbasi, Roma Raj, Latika Gupta
      Indian Journal of Rheumatology 2022 17(2):110-117
      Background: Reactive arthritis (ReA) and ankylosing spondylitis (AS), both spondyloarthropathies predominantly affecting young men seriously hamper mobility during the active phases of disease. While AS is thoroughly researched, specific studies on ReA are relatively scarce despite its pervasive nature and ever evolving epidemiology. Thus, it is imperative to understand the quality of life (QoL) of ReA patients in comparison to those with AS and healthy controls (HC) to reduce the disparity in patient care.Methods: An inception cohort of adults with ReA (Braun’s criteria) was surveyed to collect the data on demographics, clinical profile, disease activity (Bath AS Disease Activity Index [BASDAI], pain Visual Analog Scale [VAS]), functional status Bath AS Functional Index (BASFI), and QoL (ASQoL instrument) between November 2019 and January 2020. HC and AS were surveyed for the same parameters using an anonymized e-survey (SurveyMonkey.com). All the data are expressed as medians and interquartile range.Results: A total of 147 participants (62 ReA, 45 AS and 40 HC) were included. Patients with ReA were younger than those with AS and HC - 25, 29, and 28 years, respectively, and had a shorter disease duration (P < 0.0001). Baseline clinical characteristics (peripheral arthritis and enthesitis), pain VAS (body pain and back pain) were comparable in ReA and AS groups. All the clinical characteristics of ReA and AS cohorts were significant in comparison to the HC cohort. Notably, functional and activity scores of AS and ReA patients were similar, whereas all functional scores of patients with either spondyloarthropathy were significantly worse than HC (BASDAI, BASFI, ASQoL, P < 0.0001). ASQoL scores were comparable across all domains of ReA and AS except in upper limb activities where patients with ReA fared better than AS. No difference in QoL was observed between acute or chronic ReA.Conclusion: QoL in ReA and AS is comparable, thus the impact of disease on physical function must be recognized to improve patient care. Patients with ReA exhibit significantly worse QoL than HC using ASQoL instrument.
      Citation: Indian Journal of Rheumatology 2022 17(2):110-117
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_223_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Experience with macrophage activation syndrome associated with systemic
           lupus erythematosus: A single-center study from Pakistan

    • Authors: Saira Elaine Anwer Khan, Roshila Shamim, Asadullah Khan, Shabnam Batool, Muhammad Zeeshan Aslam
      Pages: 118 - 123
      Abstract: Saira Elaine Anwer Khan, Roshila Shamim, Asadullah Khan, Shabnam Batool, Muhammad Zeeshan Aslam
      Indian Journal of Rheumatology 2022 17(2):118-123
      Objective: The objective of the study was to evaluate the clinical, laboratory manifestations, and associations of macrophage activation syndrome (MAS) in a cohort of Pakistani patients with systemic lupus erythematous and to compare it with a well-characterized cohort of active systemic lupus erythematosus (SLE) without MAS.Materials and Methods: Patients with a diagnosis of SLE admitted from January 2017 to July 2019 were retrospectively reviewed. MAS ascertained by either clinical criteria or bone marrow biopsy were studied. Demographics, clinical, and laboratory parameters of MAS patients were evaluated and compared with a cohort of non-MAS active SLE.Results: A total of 305 patients of SLE were evaluated, out of these 18 patients had a diagnosis of MAS, making a MAS prevalence of 5.9%. Mean age of the patients was 27.25 ± 10.16 years. Female comprised 13 (72%) of MAS group. Fever was the most common clinical presentation (100%), followed by splenomegaly (38.9%) and lymphadenopathy (33.3%). At least 5 (27.8%0 patients had MAS as their initial manifestation. Anemia (88.9%), thrombocytopenia (88.9%), leukopenia (72%), and pancytopenia (55.6%) were prominent laboratory parameters. Mean serum ferritin of 1584 ng/ml and mean triglyceride of 270 mg/dl were reported. On comparing with non-MAS cohort; younger age, fever, lymphadenopathy, splenomegaly, mucocutaneous features, any type of cytopenia, high aspartate aminotransferase (AST), low albumin, and lactate dehydrogenase, all showed significant association with MAS (P < 0.05).Conclusion: Fever and associated cytopenias coupled with raised AST are strong predictors of MAS in patients with SLE.
      Citation: Indian Journal of Rheumatology 2022 17(2):118-123
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_230_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Therapeutic drug monitoring of mycophenolate mofetil for the treatment of
           pediatric lupus nephritis: A cross-sectional study

    • Authors: Navamani Kirubakaran, Anu Punnen, Ratna Prabha, Indira Agarwal, Sathish Kumar
      Pages: 124 - 128
      Abstract: Navamani Kirubakaran, Anu Punnen, Ratna Prabha, Indira Agarwal, Sathish Kumar
      Indian Journal of Rheumatology 2022 17(2):124-128
      Objectives: This study aimed to determine whether mycophenolic acid area under the curve 0–12 h (MPA AUC0–12) concentrations correlate with the disease activity in children with lupus nephritis.Methodology: Twenty-five children who fulfilled the inclusion criteria were recruited. MPA levels were measured at specific intervals between 0 and 12 h of drug administration, including the baseline (trough) levels. Disease activity is determined by systemic lupus erythematosus disease activity index (SLEDAI) scoring along with laboratory parameters, and serological status was also compared with MPA AUC0-12 concentrations.Results: Out of 25 children, 20 (80%) were girls and 5 (20%) were boys. Mean MPA AUC0-12 concentrations was significantly lower in patients with active disease (SLEDAI score >6) (38.46 ± 14.3 μg.h/ml) than the patients with inactive disease (SLEDAI <6) (69 ± 19.24 μg.h/ml) with a P = 0.003. MPA AUC 0-12 concentrations correlated with hemoglobin complement level (C3, C4) and SLEDAI. Multivariable analysis revealed that daily mycophenolate mofetil (MMF) doses were recognized as independent variables influencing the MPA AUC0–12 concentrations.Conclusion: Our study strongly suggests that the dose of MMF needs to be based on the MPA AUC0–12 levels.
      Citation: Indian Journal of Rheumatology 2022 17(2):124-128
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_130_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Effects of fibromyalgia syndrome in patients with diffuse systemic
           sclerosis: Evaluation with 2010 American college of rheumatology criteria
           set

    • Authors: Ayse Ayan, Hanife Hale Hekim, Sebahat Yaprak Cetin
      Pages: 129 - 135
      Abstract: Ayse Ayan, Hanife Hale Hekim, Sebahat Yaprak Cetin
      Indian Journal of Rheumatology 2022 17(2):129-135
      Backgrounds: The aim of this study was to evaluate the frequency of fibromyalgia syndrome (FMS) according to the 2010 FMS criteria and to investigate its effects on quality of life in patients with diffuse systemic sclerosis (SSc).Methods: The study included 44 SSc patients with a mean age of 52.84 ± 13.35 years and 96 healthy adults with a mean age of 53.43 ± 14.67 years. The symptom severity scale, fibromyalgia impact questionnaire, beck depression and anxiety inventory, and the short form (SF)-36 were used for evaluations in the study. FMS was detected in 27 patients with SSc (62.79%) and 13 health controls (13.5%).Results: When SF-36 subscales were compared, a statistically significant difference was found in favor of the fibromyalgia patient group in respect of physical function, physical role difficulty, mental role, and pain scores (P: 0.04-0.00).Conclusion: Our results showed that FMS frequency was increased in patients with diffuse SSc and that FMS significantly affected the quality of life. In addition, the anxiety and depression levels were also increased in SSc patients with FMS. It can be recommended to assess patients with SSc for FMS during routine clinic examinations.
      Citation: Indian Journal of Rheumatology 2022 17(2):129-135
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_112_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Effectiveness of colchicine among patients with COVID-19 infection: A
           randomized, open-labeled, clinical trial

    • Authors: Aryan Mohamadfatih Jalal, Sheelan Faroz Aref, Dashty Abbas Albustany
      Pages: 136 - 141
      Abstract: Aryan Mohamadfatih Jalal, Sheelan Faroz Aref, Dashty Abbas Albustany
      Indian Journal of Rheumatology 2022 17(2):136-141
      Background and Objective: In November 2019, there were abundant cases of COVID-19 which first case was reported in Wuhan, China. Colchicine has an important role in inhibiting activation of NLRP3 inflammasome that predispose to decrease cytokine production. This study aimed to evaluate whether colchicine is effective in treatment of corona virus disease of 2019 (COVID-19) patients or not.Patients and Methods: A randomized, open-labeled, clinical trial of Colchicine for the treatment of COVID-19, allocated between May 8, and June 18, 2021. The colchicine tablet dosage was 0.5 mg twice daily for 14 days added to the standard treatment versus control group who receive standard treatment without colchicine, with the trial registration ID: NCT04867226. The study was conducted in Erbil city-Iraq with the endpoints being clinical, laboratory parameters and duration of hospitalization.Results: Eighty patients participated in the study. Fewer patients in the colchicine group had musculoskeletal symptoms (17.5%, P = 0.001) in comparison to the patients, who received control treatment. The serum ferritin level in most of patients who treated with colchicine returned to normal in contrast to the control group, whose serum ferritin level was still high (P = 0.041). Similarly, the average of C-reactive protein and D-dimer after treatment among the colchicine group participants was significantly lower than the control group, the P values were 0.011 and 0.043 consecutively. The colchicine group patients stayed for a shorter duration at the hospital (18.4 days) compared to the control group (24.24 days). P value was 0.009. In addition to that the response and cure rate were higher in the colchicine group (56%) in the comparison to control group (43.1%).Conclusion: The colchicine drug can be effective in treating patients with COVID-19 infection by improving musculoskeletal symptoms and inhibiting inflammatory biomarkers; it is also effective in reducing duration of hospitalization.
      Citation: Indian Journal of Rheumatology 2022 17(2):136-141
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_264_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Human leukocyte antigen-B alleles in spondyloarthritides: A single-center,
           prospective, cross-sectional study

    • Authors: Jeet Hemantkumar Patel, Ved Chaturvedi, Lalit Duggal, Neeraj Jain, Gurbir Bhandari, Monika Jain
      Pages: 142 - 148
      Abstract: Jeet Hemantkumar Patel, Ved Chaturvedi, Lalit Duggal, Neeraj Jain, Gurbir Bhandari, Monika Jain
      Indian Journal of Rheumatology 2022 17(2):142-148
      Objective: The objective of this study is to study distribution of human leukocyte antigen (HLA)-B alleles in Spondyloarthritis (SpA) and to find its clinical relevance in the patient management.Materials and Methods: A prospective, cross-sectional, pilot study was carried out on 100 participants at the single center of Northern India (Sir Ganga Ram Hospital, New Delhi). Assessment in ankylosing spondylitis (ASAS) classification criteria for axial/peripheral spondyloarthritis (SPA) (conventionally AS-ankylosing spondylitis), classification criteria for reactive arthritis (ReA), and CASPAR (classification criteria for psoriatic arthritis) criteria for psoriatic arthritis were used to sub-classify patients. Inflammatory bowel disease (IBD) patients who classified for ASAS criteria for SPA were classified as IBD-related SPA. Demographic data, disease characteristics, and relevant investigations were noted. HLA-B genotyping was carried out by the polymerase chain reaction method. HLA-B genotyping of 100 healthy kidney transplant donors were taken as controls. Fisher's exact test was used. P < 0.05 was considered as statistically significant.Results: Out of 100 patients, 58 were male and 42 were female. SPA (AS), ReA, PSA, and IBD-related SPA were 65, 12, 16, and 07, respectively. HLA-B 27+ve participants were 57. HLA-B40 and HLA-B52 were present in 25 and 19 participants, respectively. HLA-B27 allele was associated with SPA, PSA, and IBD-related SPA (P < 0.01, 0.034, and 0.037, respectively). In HLA-B27-ve cases, the frequency of HLA-B40 was increased (P value – 0.033, odds ratio [OR] with 95% confidence interval-2.44, [1.09, 5.48]). Similarly, the frequency of HLA-B15 and HLA-B13 were increased in PSA (P value – 0.034, 0.020 with OR – 4.09, 6.33, respectively). The presence of HLA-B27 allele favored axial ± peripheral disease while its absence favored peripheral disease (P value– 0.019). HLA-B27+ve participants had more active disease compared to HLA-B27-ve and HLA-B40+ve cases (P < 0.01 and 0.013, respectively).Conclusion: The utility of HLA-B alleles other than HLA-B27 is limited in SpA patients' management. To find their use in diagnosis, prognosis and treatment need further studies.xs
      Citation: Indian Journal of Rheumatology 2022 17(2):142-148
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_296_20
      Issue No: Vol. 17, No. 2 (2022)
       
  • Clinical characteristics and outcomes of macrophage activation syndrome
           among patients attending a rheumatology tertiary care center in North
           India

    • Authors: Rasmi Ranjan Sahoo, Manesh Manoj, Prashant Bafna, Kasturi Hazarika, Anupam Wakhlu
      Pages: 149 - 152
      Abstract: Rasmi Ranjan Sahoo, Manesh Manoj, Prashant Bafna, Kasturi Hazarika, Anupam Wakhlu
      Indian Journal of Rheumatology 2022 17(2):149-152
      Background: Macrophage activation syndrome (MAS) is a potentially fatal condition complicating several rheumatologic disorders. This retrospective analysis studied the clinical characteristics and outcomes of patients diagnosed with MAS from a rheumatology tertiary care center.Methods: Pediatric and adult patients diagnosed with rheumatologic disorders and fulfilling the 2016 European League against Rheumatism/American College of Rheumatology classification criteria for MAS associated with systemic juvenile idiopathic arthritis (sJIA) or the hemophagocytic lymphohistiocytosis (2004) criteria, as appropriate, were included over a period of 1 year. Detailed clinical history and laboratory parameters were extracted from the patients' records. Treatment details, duration of hospitalization, and outcomes were recorded.Results: The study included nine patients (five males and four females) with a median age of 27 years, range 10–48 years. The median duration of illness was 6 months, range 2–60 months. Five patients were diagnosed with systemic lupus erythematosus, two patients with adult-onset Still's disease, and one each with sJIA and sarcoidosis. Infection (three patients), malignancy (one patient), and uncontrolled or aggressive disease (five patients) were recognized as the possible precipitating factors. Three patients had pancytopenia at presentation, whereas bicytopenia was observed in five patients. Hemophagocytosis on bone marrow biopsy was seen in seven patients. The median duration of hospital stay was 3 weeks, range 2–4 weeks. High-dose steroids were administered to all patients, along with oral cyclosporine in seven patients. One patient was given weekly etoposide infusion for unabated MAS. Two patients expired.Conclusion: Prompt diagnosis and aggressive treatment strategy are pivotal for improving prognosis in MAS complicating rheumatologic disorders.
      Citation: Indian Journal of Rheumatology 2022 17(2):149-152
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_70_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Coronavirus Disease-19 associated arthritis &#8211; An
           observational study

    • Authors: Debanjali Sinha, Sumantro Mondal, Alakendu Ghosh
      Pages: 153 - 156
      Abstract: Debanjali Sinha, Sumantro Mondal, Alakendu Ghosh
      Indian Journal of Rheumatology 2022 17(2):153-156
      Background: The coronavirus disease or COVID-19 pandemic is the major global health crisis of the present time. Various rheumatological manifestations have been reported during or after COVID-19 infection, but data are scarce. In this observational study, we have tried to analyze the clinical characteristics of COVID-19 associated arthralgia/arthritis.Methods: We have collected the clinical data of 14 patients over the past 6 months who have developed arthralgia or arthritis during or after symptomatic COVID-19 infection, proven by a positive reverse transcription-polymerase chain reaction test from nasopharyngeal swab.Results: The most common symptoms during COVID-19 infection in the 14 patients were fever and myalgia, being present in 92.8% and 64.3% patients, respectively. Arthralgia/arthritis occurred at a mean interval of 20 days (range: 0–60 days). Knee was the most commonly involved joint (78.6%), followed by the wrist and metacarpophalangeal joints (each in 57.1%). Enthesitis was documented in 21.4% patients. The mean duration of COVID-19 associated arthralgia or arthritis was 53.9 days (range: 7–210 days). In 85.7% patients, joint pains improved within 2 months; in only a small proportion of patients (14.3%), joint pains persisted after 6 months. Nonsteroidal anti-inflammatory drugs (NSAIDs) (given in 64.3% patients) and corticosteroids (in 50%) were the most commonly prescribed and effective treatment options.Conclusion: COVID-19 infections mostly caused reactive arthritis, though acute and chronic arthritis is also seen. In the majority of cases, arthritis started about 3 weeks after COVID-19 infection and subsided within 2 months. NSAIDs and corticosteroids are the most effective treatment options.
      Citation: Indian Journal of Rheumatology 2022 17(2):153-156
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_133_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Arterial stiffness in rheumatoid arthritis: Current knowledge and future
           perspectivess

    • Authors: Panagiota Anyfanti, Eleni Bekiari, Elena Angeloudi, Eleni Pagkopoulou, George D Kitas, Theodoros Dimitroulas
      Pages: 157 - 165
      Abstract: Panagiota Anyfanti, Eleni Bekiari, Elena Angeloudi, Eleni Pagkopoulou, George D Kitas, Theodoros Dimitroulas
      Indian Journal of Rheumatology 2022 17(2):157-165
      Rheumatoid arthritis (RA) is characterized by the excess cardiovascular risk that remains essentially unaltered despite current medical advances. The introduction of reliable markers towards early identification and subsequently effective management of high-risk patients with RA are urgently needed. Arterial stiffness represents an early indicator of cardiovascular morbidity and mortality and has emerged as a surrogate marker of cardiovascular disease. From a pathophysiological perspective, it is significantly accelerated by the accumulation of cardiovascular risk factors and is considered an intermediate process towards the development and progression of atherosclerotic cardiovascular disease. The aim of this review is to critically upraise current knowledge on arterial stiffness in patients with RA. Although not all studies concur, increased Pulse Wave Velocity (PWV) has been repeatedly reported in patients with RA. However, results need to be interpreted with caution as most studies enrolled patients with multiple cardiovascular risk factors and/or established cardiovascular disease, or with uncontrolled RA with high levels of systemic inflammation. Whether and to which extent increased arterial stiffness among patients with RA is associated with the disease per se, or rather represents the composite effect of hypertension and other classical cardiovascular risk factors, warrants further investigation. The impact of antirheumatic drugs on arterial stiffness is also discussed. Considering the well-established predictive value of increased PWV both in the general population and patients at high cardiovascular risk, future studies need to focus on the clinical utility of this surrogate risk marker specifically in patients with RA.
      Citation: Indian Journal of Rheumatology 2022 17(2):157-165
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_254_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Infliximab in treatment of refractory multisystem inflammatory syndrome in
           children with severe cardiac dysfunction

    • Authors: Guruprasad Hassan Shankar, Jitendra S Oswal, Bhakti U Sarangi, Ajay Walimbe, Prithvichandra Markal, Karthik V Badarayan
      Pages: 166 - 169
      Abstract: Guruprasad Hassan Shankar, Jitendra S Oswal, Bhakti U Sarangi, Ajay Walimbe, Prithvichandra Markal, Karthik V Badarayan
      Indian Journal of Rheumatology 2022 17(2):166-169
      Multisystem inflammatory syndrome in children (MIS-C) has emerged as one of the several challenges thrown by the ongoing severe acute respiratory syndrome-coronavirus 2 pandemic. Although diagnostic criteria of MIS-C have now been established to raise the clinical suspicion for the condition, the Kawasaki disease (KD)-like phenotype of MIS-C presents with additional therapeutic dilemmas. The treatment guidance till date remains empirical with consideration of intravenous immunoglobulin (IVIG) and glucocorticoids. However, treatment of cases refractory to the current conventional therapy with respect to biologics remains uncertain. We describe here, an 8-year-old boy with MIS-C (KD-like phenotype) with severe cardiac dysfunction refractory to IVIG and pulse methylprednisolone who responded to tumor necrosis factor-α inhibition using infliximab.
      Citation: Indian Journal of Rheumatology 2022 17(2):166-169
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_21_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Bacillus calmette&#8211;Gu&#233;rin scar inflammation after
           COVID vaccination

    • Authors: BN Shiva Prasad
      Pages: 170 - 173
      Abstract: BN Shiva Prasad
      Indian Journal of Rheumatology 2022 17(2):170-173
      Bacillus Calmette–Guérin (BCG) scar inflammatory reactions have been commonly reported with Kawasaki disease in children and less commonly with other viral infections. Postvaccination BCG scar inflammation has only been reported with the influenza vaccine. Two cases of post-COVID vaccination BCG scar inflammation has been recently reported. we report a case of BCG scar inflammation appeared after 24 h of vaccination of both the doses of vaccine.
      Citation: Indian Journal of Rheumatology 2022 17(2):170-173
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_194_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Sacroiliitis as presenting manifestation in immune-mediated inflammatory
           disorders other than spondyloarthritis: Case series and review of
           literature

    • Authors: Kunal Chandwar, Kriti Kishor, PM Ankush, Mukesh Kumar Maurya, Puneet Kumar, Urmila Dhakad
      Pages: 174 - 179
      Abstract: Kunal Chandwar, Kriti Kishor, PM Ankush, Mukesh Kumar Maurya, Puneet Kumar, Urmila Dhakad
      Indian Journal of Rheumatology 2022 17(2):174-179
      Sacroiliitis has long been thought to be a fiefdom of the spondyloarthritides. We present 5 different cases of Immune mediated inflammatory disorders (IMIDs) presenting with sacroilitis. Though sacroilitis on Imaging can be seen in postpartum women, Athletes and even normal people, erosions in sacroiliac joint and deep SI joint edema are likely to favour a pathological cause of sacroilitis seen on imaging. We also review the prevalence of sacroilitis in different IMIDs from the available literature.
      Citation: Indian Journal of Rheumatology 2022 17(2):174-179
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_246_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Childhood-onset enthesitis-related arthritis leading to nephrotic syndrome
           due to secondary amyloidosis complicated by acute pulmonary embolism - The
           domino effect

    • Authors: Vishal Mangal, Bhaskar Datt, Arun Hegde, AW Kashif, Ankit Kumar, Jaspreet Kaur, Nidhi Goel, Anil Shankar Menon
      Pages: 180 - 185
      Abstract: Vishal Mangal, Bhaskar Datt, Arun Hegde, AW Kashif, Ankit Kumar, Jaspreet Kaur, Nidhi Goel, Anil Shankar Menon
      Indian Journal of Rheumatology 2022 17(2):180-185
      The prevalence of Juvenile idiopathic arthritis (JIA) in India is 0.001% among the population under 16 years old and 0.00029% among the total population. Of the total JIA population, enthesitis-related arthritis (ERA) constitutes 35% of the cases. In the past, chronic infections, mainly, tuberculosis were the most common cause of AA amyloidosis in India; however, chronic inflammatory arthropathies have become the most common cause of AA amyloidosis in India over the past three to four decades. In 95% of the patients with AA amyloidosis, the kidney is the most affected organ presenting as proteinuria of nephrotic syndrome. The prevalence of AA amyloidosis in JIA is estimated to be 7.7% and 3.1% among the ERA group, making it an infrequent association. This translates to one case of AA amyloidosis secondary to ERA per 1,00,000,00 population in India. Similarly, the incidence of pulmonary thromboembolism in patients with nephrotic syndrome is 7.8%. We present a case of a young male who was diagnosed with JIA-ERA at the age of 13 years with multiple flares in childhood had now developed nephrotic syndrome secondary to AA amyloidosis demonstrated on renal biopsy complicated by acute pulmonary embolism and occult hepatitis B infection. He was managed with anti-tumor necrosis factor inhibitor therapy with a favorable outcome. This is the first such case of multiple rare associations occurring together in a single patient to the best of our knowledge.
      Citation: Indian Journal of Rheumatology 2022 17(2):180-185
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_160_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • IgA vasculitis post-ChAdOx1 nCoV-19 vaccine in a patient with rheumatoid
           arthritis

    • Authors: Kunal Chandwar, Digvijay Gajanan Ekbote, Juhi Dixit, Kriti Kishor, Kiran Preet Malhotra, Urmila Dhakad
      Pages: 186 - 187
      Abstract: Kunal Chandwar, Digvijay Gajanan Ekbote, Juhi Dixit, Kriti Kishor, Kiran Preet Malhotra, Urmila Dhakad
      Indian Journal of Rheumatology 2022 17(2):186-187

      Citation: Indian Journal of Rheumatology 2022 17(2):186-187
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_205_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Vaccine hesitancy in patients with autoimmune diseases: Data from the
           coronavirus disease-2019 vaccination in autoimmune diseases study

    • Authors: Parikshit Sen, James B Lilleker, Vishwesh Agarwal, Sinan Kardes, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Albert Selva O&#39;Callaghan, Elena Nikiphorou, Ai Lyn Tan, Lorenzo Cavagna, Miguel A Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Masataka Kuwana, Giovanni Cagnotto, Arvind Nune, Oliver Distler, Hector Chinoy, Rohit Aggarwal, Latika Gupta
      Pages: 188 - 191
      Abstract: Parikshit Sen, James B Lilleker, Vishwesh Agarwal, Sinan Kardes, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Albert Selva O'Callaghan, Elena Nikiphorou, Ai Lyn Tan, Lorenzo Cavagna, Miguel A Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Masataka Kuwana, Giovanni Cagnotto, Arvind Nune, Oliver Distler, Hector Chinoy, Rohit Aggarwal, Latika Gupta
      Indian Journal of Rheumatology 2022 17(2):188-191

      Citation: Indian Journal of Rheumatology 2022 17(2):188-191
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_221_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • The perils of generic small molecules: Has tofacitinib become a toffee

    • Authors: Kunal Chandwar, Prasanna Dogga, Juhi Dixit, Digvijay Gajanan Ekbote, Kriti Kishor
      Pages: 192 - 192
      Abstract: Kunal Chandwar, Prasanna Dogga, Juhi Dixit, Digvijay Gajanan Ekbote, Kriti Kishor
      Indian Journal of Rheumatology 2022 17(2):192-192

      Citation: Indian Journal of Rheumatology 2022 17(2):192-192
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_204_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • The changing paradigm of glucocorticoid therapy in antineutrophil
           cytoplasmic antibody-associated vasculitis

    • Authors: Kunal Chandwar, Chandani Shah, Puja Srivastava
      Pages: 193 - 195
      Abstract: Kunal Chandwar, Chandani Shah, Puja Srivastava
      Indian Journal of Rheumatology 2022 17(2):193-195

      Citation: Indian Journal of Rheumatology 2022 17(2):193-195
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_283_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Is T-helper 17 inhibition the knight in shining armor we were looking for?
           Comments on the article by shumy et al.

    • Authors: Kunal Chandwar, Chandani J Shah, Puja Srivastava
      Pages: 196 - 198
      Abstract: Kunal Chandwar, Chandani J Shah, Puja Srivastava
      Indian Journal of Rheumatology 2022 17(2):196-198

      Citation: Indian Journal of Rheumatology 2022 17(2):196-198
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_69_22
      Issue No: Vol. 17, No. 2 (2022)
       
  • Optimizing corticosteroid therapy in takayasu arteritis

    • Authors: Pallavi Patro
      Pages: 199 - 199
      Abstract: Pallavi Patro
      Indian Journal of Rheumatology 2022 17(2):199-199

      Citation: Indian Journal of Rheumatology 2022 17(2):199-199
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_41_22
      Issue No: Vol. 17, No. 2 (2022)
       
  • Comment to “Does gender gap exist in indian rheumatology? Analysis
           of faculty gender representation at its annual conferences” by
           Mohansundaram et al.

    • Authors: Sahla Sathar, Nivedita Jha, Molly Mary Thabah
      Pages: 200 - 201
      Abstract: Sahla Sathar, Nivedita Jha, Molly Mary Thabah
      Indian Journal of Rheumatology 2022 17(2):200-201

      Citation: Indian Journal of Rheumatology 2022 17(2):200-201
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_138_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Unilateral retinopathy in a case of systemic lupus erythematosus

    • Authors: Pradeep Kumar Panigrahi, Lipika Mehra
      Pages: 202 - 203
      Abstract: Pradeep Kumar Panigrahi, Lipika Mehra
      Indian Journal of Rheumatology 2022 17(2):202-203

      Citation: Indian Journal of Rheumatology 2022 17(2):202-203
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_244_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Assessing the risk of retinopathy in indian patients using
           hydroxychloroquine for rheumatic and musculoskeletal diseases: A
           retrospective observational study – Reply

    • Authors: Arindam Nandy Roy, Vinitha Samala, Yarram Ashok Kumar, Syeda Sana Fatima
      Pages: 204 - 205
      Abstract: Arindam Nandy Roy, Vinitha Samala, Yarram Ashok Kumar, Syeda Sana Fatima
      Indian Journal of Rheumatology 2022 17(2):204-205

      Citation: Indian Journal of Rheumatology 2022 17(2):204-205
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_6_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • New-onset henoch&#8211;Schonlein purpura after COVID-19 vaccination

    • Authors: Rija Mathew Roy, Anna Mani, Joseph John, Thomas Antony, Lydia Jacob
      Pages: 206 - 207
      Abstract: Rija Mathew Roy, Anna Mani, Joseph John, Thomas Antony, Lydia Jacob
      Indian Journal of Rheumatology 2022 17(2):206-207

      Citation: Indian Journal of Rheumatology 2022 17(2):206-207
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_226_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Anti-synthetase syndrome masquerading as COVID-19

    • Authors: Rajat Kharbanda, Neeraj Jain, Latika Gupta
      Pages: 208 - 209
      Abstract: Rajat Kharbanda, Neeraj Jain, Latika Gupta
      Indian Journal of Rheumatology 2022 17(2):208-209

      Citation: Indian Journal of Rheumatology 2022 17(2):208-209
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_180_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Granulomatosis with polyangiitis and COVID-19 pneumonia

    • Authors: Arvind Nune, Karthikeyan P Iyengar, D Mulherin, Pranav Ish, CA Musat, Hem Raj Sapkota
      Pages: 210 - 212
      Abstract: Arvind Nune, Karthikeyan P Iyengar, D Mulherin, Pranav Ish, CA Musat, Hem Raj Sapkota
      Indian Journal of Rheumatology 2022 17(2):210-212

      Citation: Indian Journal of Rheumatology 2022 17(2):210-212
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_235_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Hydroxychloroquine in COVID-19 widespread use despite unproven benefit

    • Authors: Pranav Ish
      Pages: 213 - 213
      Abstract: Pranav Ish
      Indian Journal of Rheumatology 2022 17(2):213-213

      Citation: Indian Journal of Rheumatology 2022 17(2):213-213
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_7_22
      Issue No: Vol. 17, No. 2 (2022)
       
  • The emergence of rheumatic immune-mediated inflammatory disease
           manifestations following SARS-CoV-2 vaccination

    • Authors: Arvind Nune, Hem Raj Sapkota, Karthikeyan P Iyengar
      Pages: 214 - 215
      Abstract: Arvind Nune, Hem Raj Sapkota, Karthikeyan P Iyengar
      Indian Journal of Rheumatology 2022 17(2):214-215

      Citation: Indian Journal of Rheumatology 2022 17(2):214-215
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_145_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • Herpes zoster reactivation after COVID-19 vaccination in patients with
           autoimmune diseases

    • Authors: Srinivasan Sanjay, Deepika Ponnuru, Sharath Kumar, Vijay K R Rao, Ankush Kawali, Padmamalini Mahendradas
      Pages: 216 - 221
      Abstract: Srinivasan Sanjay, Deepika Ponnuru, Sharath Kumar, Vijay K R Rao, Ankush Kawali, Padmamalini Mahendradas
      Indian Journal of Rheumatology 2022 17(2):216-221

      Citation: Indian Journal of Rheumatology 2022 17(2):216-221
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_137_21
      Issue No: Vol. 17, No. 2 (2022)
       
  • How to practice academic medicine and publish from developing
           countries? A practical guide

    • Authors: Madhuri H Radhakrishna, Vinod Ravindran
      Pages: 222 - 223
      Abstract: Madhuri H Radhakrishna, Vinod Ravindran
      Indian Journal of Rheumatology 2022 17(2):222-223

      Citation: Indian Journal of Rheumatology 2022 17(2):222-223
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_2_22
      Issue No: Vol. 17, No. 2 (2022)
       
  • Glucocorticoids in rheumatology

    • Authors: Shrikant Wagh
      Pages: 224 - 224
      Abstract: Shrikant Wagh
      Indian Journal of Rheumatology 2022 17(2):224-224

      Citation: Indian Journal of Rheumatology 2022 17(2):224-224
      PubDate: Mon,13 Jun 2022
      DOI: 10.4103/injr.injr_20_22
      Issue No: Vol. 17, No. 2 (2022)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.239.4.127
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-